Metraipolis › archive › dc_c0f482dbe702

Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment — Europe PMC PMID:40873276

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40873276
DOI
10.2174/011570159x392955250815095236
License (as archived)
solo-consultazione
Archived
2026-11-07T06:32:02.714Z
SHA-256 of the archived text
35a58774b80002e0af31969b590a6b0669507acf6da5e4be0dff6e21c76641ca
Stable URL of this page
https://metraipolis.com/documento/dc_c0f482dbe702

How to cite

Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment — Europe PMC PMID:40873276 — Europe PMC (en), https://europepmc.org/article/MED/40873276 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c0f482dbe702 (Metraipolis archive dc_c0f482dbe702, sha256 35a58774b80002e0af31969b590a6b0669507acf6da5e4be0dff6e21c76641ca)
BibTeX
@misc{dcc0f482dbe702,
  title = {Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment — Europe PMC PMID:40873276},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40873276},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c0f482dbe702; sha256 35a58774b80002e0af31969b590a6b0669507acf6da5e4be0dff6e21c76641ca},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40873276. Agents can read the archived copy with the MCP tool read_document.